Historical record - last NADAC effective date: 1/15/2019
Product Information
EXFORGE 5-320 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $10.9314 per EA under NDC 00078049015. Its NADAC has been published 321 times since Nov 28, 2013.
FDA first approved this application on Jun 20, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 320 mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078049015
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
1/15/2019
Active Ingredients
AMLODIPINE BESYLATE; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA021990FDA Approved
6/20/2007
TE Code
AB
On Market Since
6/20/2007
Pharmacological Classes
Price Statistics
The NADAC for EXFORGE 5-320 MG TABLET has been published 321 times since Nov 28, 2013, and over the history we have for it it has risen 100.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.9314 per EA |
|---|---|
| All-time high | $10.9314 (Jan 15, 2020) |
| All-time low | $5.4505 (Nov 28, 2013) |
| Median price | $9.0114 |
| Average price | $8.6953 |
| Largest weekly change | +19.5% (Apr 15, 2015) |
| Weeks tracked | 321 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+100.6%
Last surveyed Jan 15, 2020 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the amlodipine besylate and valsartan market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
amlodipine besylate and valsartan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EXFORGE 5-320 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EXFORGE 5-320 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $10.9314 per EA (NDC 00078049015), effective Jan 15, 2020.
How has the price of EXFORGE 5-320 MG TABLET changed over time?
Over the history we have for it, the NADAC for EXFORGE 5-320 MG TABLET has risen 100.6%. It has been tracked across 321 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EXFORGE 5-320 MG TABLET?
Since Nov 28, 2013, the NADAC for EXFORGE 5-320 MG TABLET has ranged from a low of $5.4505 (Nov 28, 2013) to a high of $10.9314 (Jan 15, 2020), with a median of $9.0114 per EA.
Are there cheaper alternatives to EXFORGE 5-320 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of EXFORGE 5-320 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EXFORGE 5-320 MG TABLET?
EXFORGE 5-320 MG TABLET (NDC 00078049015) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.